A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Determine the Effect of QVA149 on Mean 24-hours Heart Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Determine the Effect of QVA149 on Mean 24-hours Heart Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 15 Mar 2012 This trial is recruiting in France, Spain.
    • 08 Dec 2009 Planned number of patients changed from 250 to 257 as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Tolerability results were reported at the 19th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top